American Society of Hematology

SHERPA: Blue

People

  1. Horwitz
    Horwitz
  2. Moskowitz
    Moskowitz
  3. Palomba
    Palomba
  4. Zelenetz
    Zelenetz
  5. Epstein-Peterson
    Epstein-Peterson
  6. Falchi
    Falchi
  7. Hamlin
    Hamlin
  8. Kumar
    Kumar
  9. Noy
    Noy
  10. Salles
    Salles

Groups

  1. Sloan Kettering Institute Postdocs (50)
  2. Center for Hematologic Malignancies (45)
  3. Department of Medicine (45)
  4. Hematologic Malignancies, Division of (45)
  5. Lymphoma (44)
  6. Hematology-Oncology Fellows (39)
  7. Population Sciences Research Program (33)
  8. Weinberg Fellows (32)
  9. GME, Medicine (26)
  10. Graduate Medical Education (26)
Search Within
  1. "Paola Ghione"
Formats
  1. Meeting Abstract (41)
  2. Journal Article (9)
Groups
  1. Sloan Kettering Institute Postdocs (50)
  2. Center for Hematologic Malignancies (45)
  3. Department of Medicine (45)
  4. Hematologic Malignancies, Division of (45)
  5. Lymphoma (44)
  6. Hematology-Oncology Fellows (39)

More Groups

People
  1. Paola Ghione (50)
  2. Steven Horwitz (33)
  3. Alison Moskowitz (31)
  4. Maria Palomba (29)
  5. Andrew Zelenetz (25)
  6. Anita Kumar (24)

More People

Years
  1. 2025 (1)
  2. 2024 (19)
  3. 2023 (16)
  4. 2022 (2)
  5. 2021 (3)
  6. 2020 (5)

More Years

Publications
  1. Blood (45)
  2. Blood Advances (5)

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BRCA1/2 impact on the development of implant-associated lymphoma in women with breast cancer and textured implants
    Journal Article

    Ghione, P.; Mandelker, D.; Arcila, M.; Seshan, V.; Terry, M. B.; Vijai, J.; Cordeiro, P.; Vanderbilt, C.; Pressley, J.; Chan, A.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Rituximab plus /- ibrutinib as first line therapy for marginal zone lymphoma
    Meeting Abstract

    Noy, A.; Thet, W. S.; Vemuri, S.; Seshan, V.; Batlevi, C. L.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Habermann, T. M.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Sequential R-CHOP/(R)-ICE and dose-adjusted EPOCH-R are both appropriate frontline treatments for newly diagnosed primary mediastinal B-cell lymphoma: Results of a retrospective analysis
    Meeting Abstract

    Bantilan, K. S.; Luttwak, E.; Moskowitz, C. H.; Matasar, M.; Straus, D. J.; Portlock, C. S.; Moskowitz, A.; Noy, A.; Palomba, M. L.; Horwitz, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Angioimmunoblastic versus non-angioimmunoblastic nodal T-follicular helper cell lymphomas: Single center retrospective analysis on 208 cases
    Meeting Abstract

    Sordi, B.; Eren, O. C.; Ganesan, N.; Iyengar, V.; Stuver, R.; Johnson, W. T.; Moskowitz, A.; Ghione, P.; Galasso, N.; Casper, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A prospective geriatric assessment (GA) study predicting toxicities in older adults (OA) with non-Hodgkin Lymphoma (NHL): Timed up and go test (TUG) time emerges as a functional vital sign
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Truong, R.; Qiu, A.; Amador, W. R.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save